2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Endocrine
2
Breast
2
Conditions
Carcinoma, Non-Small-Cell Lung
57
Breast Neoplasms
35
Neoplasms
32
Parkinson Disease 4, Autosomal Dominant Lewy Body
26
Multiple Myeloma
24
Leukemia, Myeloid, Acute
21
Recurrence
20
Colorectal Neoplasms
17
Neoplasm Metastasis
17
Carcinoma, Renal Cell
15
Lymphoma, Non-Hodgkin
15
Ovarian Neoplasms
15
Leukemia
14
Leukemia, Lymphocytic, Chronic, B-Cell
14
Melanoma
14
Lymphoma, Follicular
12
Precursor Cell Lymphoblastic Leukemia-Lymphoma
12
Lung Neoplasms
11
Myelodysplastic Syndromes
11
Urinary Bladder Neoplasms
11
Carcinoma, Hepatocellular
10
Hematologic Neoplasms
10
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
10
Adenocarcinoma
9
Glioma
9
Lymphoma
9
Lymphoma, Large B-Cell, Diffuse
9
Lymphoma, Mantle-Cell
9
Prostatic Neoplasms
9
Stomach Neoplasms
9
Interventions
Fulvestrant
2
ribociclib
1
Alpelisib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Has announcements
×
Multiple Endocrine Neoplasia Type 1
×
Clear all
NCT02437318
2025-02-13
SOLAR-1
Novartis
Phase 3
Completed
572 enrolled
22 charts
1 FDA
NCT02422615
2023-11-30
MONALEESA-3
Novartis
Phase 3
Completed
726 enrolled
17 charts
1 FDA